News Regeneron Pharmaceuticals, Inc. Sao Paulo

Equities

REGN34

BRREGNBDR005

Delayed Sao Paulo Other stock markets 12:12:23 2024-07-11 pm EDT			5-day change	1st Jan Change
98.14 ^BRL	+25.19%		+4.38%	+44.09%

02:40pm	Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183	MT
Jul. 10	Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050	MT

Summary

Unlock all the news: Be the first to know and act before the market!

100% Free Registration

Morgan Stanley Trims Price Target on Regeneron Pharmaceuticals to $1,182 From $1,183	08:40am	MT
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	07:29pm	PR
Barclays Adjusts Price Target on Regeneron Pharmaceuticals to $1,200 From $1,050	Jul. 10	MT
RBC Lifts Price Target on Regeneron Pharmaceuticals to $1,232 From $1,229, Keeps Outperform Rating	Jul. 09	MT
PTAB Invalidates Regeneron Claims On Method Of Treatment	Jul. 08	AQ
Regeneron Expects Earnings Hit After $24 Million R&D Charge	Jul. 08	DJ
Sanofi - Dupixent approved in the EU as the first-ever targeted therapy for patients with COPD	Jul. 04	AQ
REGENERON PHARMACEUTICALS, INC. - DUPIXENT APPROVED IN THE EUROPEAN UNION AS THE FIRST-EVER TARGETED THERAPY FOR PATIENTS WITH COPD	Jul. 04	AQ
Regeneron, Sanofi Say Chronic Obstructive Pulmonary Disease Treatment Gains European Approval	Jul. 03	MT
Sanofi obtains EU approval for Dupixent	Jul. 03	RE
Sanofi, Regeneron Get EU Approval for Dupixent to Treat Respiratory Disease	Jul. 03	DJ
EU approves Sanofi's Dupixent for 'smoker's lungs'	Jul. 03	RE
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD	Jul. 03	GL
Dupixent® (dupilumab) Approved in the European Union as the First-ever Targeted Therapy for Patients with COPD	Jul. 03	AQ
Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD	Jul. 03	CI
Regeneron Pharmaceuticals Insider Sold Shares Worth $1,190,564, According to a Recent SEC Filing	Jul. 02	MT
Kuehn Law Encourages Investors of Regeneron Pharmaceuticals, Inc. to Contact Law Firm	Jul. 02	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Regeneron Pharmaceuticals, Inc. - REGN	Jul. 02	PR
REGENERON - ODRONEXTAMAB RECOMMENDED FOR EU APPROVAL BY THE CHMP TO TREAT RELAPSED, REFRACTORY FOLLICULAR LYMPHOMA AND DIFFUSE LARGE B-CELL LYMPHOMA	Jul. 01	AQ
Regeneron Pharmaceuticals, Inc.(NasdaqGS:REGN) dropped from Russell 1000 Dynamic Index	Jun. 30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Regeneron Pharmaceuticals, Inc. Sao Paulo

Equities

REGN34

BRREGNBDR005

Summary

Filters